Showing 1 - 15 results of 15 for search 'Sandra Robrecht', query time: 0.06s Refine Results
  1. 1
    Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)

    Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG) by Sonia Jaramillo, Andreas Agathangelidis, Christof Schneider, Jasmin Bahlo, Sandra Robrecht, Eugen Tausch, Johannes Bloehdorn, Manuela Hoechstetter, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Michael Hallek, Hartmut Döhner, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos, Stephan Stilgenbauer

    Published 2019-12-01
    Get full text
    Article
  2. 2
    Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients

    Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients by Johannes Bloehdorn, Julia Krzykalla, Karlheinz Holzmann, Andreas Gerhardinger, Billy Michael Chelliah Jebaraj, Jasmin Bahlo, Kathryn Humphrey, Eugen Tausch, Sandra Robrecht, Daniel Mertens, Christof Schneider, Kirsten Fischer, Michael Hallek, Hartmut Döhner, Axel Benner, Stephan Stilgenbauer

    Published 2021-03-01
    Get full text
    Article
  3. 3
    SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia

    SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia by Sibylle C. Mellinghoff, Leonie Mayer, Sandra Robrecht, Leonie M. Weskamm, Christine Dahlke, Henning Gruell, Maike Schlotz, Kanika Vanshylla, Hans A. Schloser, Martin Thelen, Anna-Maria Fink, Kirsten Fischer, Florian Klein, Marylyn M. Addo, Barbara Eichhorst, Michael Hallek, Petra Langerbeins

    Published 2022-06-01
    Get full text
    Article
  4. 4
    Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies

    Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies by Natali Pflug, Geothy Chakupurakal, Anna-Maria Fink, Sandra Robrecht, Marco Herling, Paula Cramer, Udo Holtick, Sebastian Theurich, Johannes Schetelig, Kirsten Fischer, Matthias Ritgen, Christof Scheid, Barbara Eichhorst, Peter Dreger, Michael Hallek, Michael von Bergwelt-Baildon, on behalf of the German CLL Study Group

    Published 2021-12-01
    Get full text
    Article
  5. 5
    P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS

    P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BI... by Deyan Yosifov, Julia von Tresckow, Adam Giza, Sandra Robrecht, Christof Schneider, Billy Jebaraj, Daniel Mertens, Matthias Ritgen, Anke Schilhabel, Karl-Anton Kreuzer, Anna Maria Fink, Othman Al-Sawaf, Petra Langerbeins, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer, Paula Cramer, Eugen Tausch

    Published 2023-08-01
    Get full text
    Article
  6. 6
    S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

    S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY by Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna-Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Liliya Sivcheva, Carsten Niemann, Anthony Schwarer, Javier Loscertales Pueyo, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Eva Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer

    Published 2023-08-01
    Get full text
    Article
  7. 7
    P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL

    P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PH... by Florian Simon, Rudy Ligtvoet, Thomas Noesslinger, Jan-Paul Bohn, Julia Von Tresckow, Rüdiger Liersch, Tobias Gaska, Kathleen Jentsch-Ullrich, Michael Koenigsmann, Thomas Wolff, Ingo Schwaner, Dominik Wolf, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Karl-Anton Kreuzer, Sandra Robrecht, Anna-Maria Fink, Moritz Fürstenau, Kirsten Fischer, Valentin Goede, Michael Hallek, Barbara Eichhorst

    Published 2023-08-01
    Get full text
    Article
  8. 8
    S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL

    S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CO... by Petra Langerbeins, Sandra Robrecht, Pascal Nieper, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Christof Schneider, Lothar Müller, Michael Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

    Published 2023-08-01
    Get full text
    Article
  9. 9
    Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial

    Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial by Paula Cramer, Julia v. Tresckow, Sandra Robrecht, Jasmin Bahlo, Moritz Fürstenau, Petra Langerbeins, Natali Pflug, Othman Al-Sawaf, Werner J. Heinz, Ursula Vehling-Kaiser, Jan Dürig, Eugen Tausch, Manfred Hensel, Stephanie Sasse, Anna-Maria Fink, Kirsten Fischer, Karl-Anton Kreuzer, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

    Published 2020-02-01
    Get full text
    Article
  10. 10
    Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

    Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia by Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer

    Published 2023-04-01
    Get full text
    Article
  11. 11
    Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

    Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymph... by Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer

    Published 2023-10-01
    Get full text
    Article
  12. 12
    The role of trephine bone marrow biopsies in the era of measurable residual disease—Results from the CLL10 trial of the German CLL Study Group (GCLLSG)

    The role of trephine bone marrow biopsies in the era of measurable residual disease—Results from the CLL10 trial of the German CLL Study Group (GCLLSG) by Nadine Kutsch, Sandra Robrecht, Anna Fink, Elisabeth Lange, Rudolf Weide, Michael G. Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling‐Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Michael R. Clausen, Ilske Oschlies, Matthias Ritgen, Marco Herling, Kirsten Fischer, Hartmut Döhner, Clemens‐Martin Wendtner, Karl‐Anton Kreuzer, Stephan Stilgenbauer, Michael Hallek, Sebastian Böttcher, Wolfram Klapper, Barbara Eichhorst

    Published 2024-07-01
    Get full text
    Article
  13. 13
    Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription

    Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription by Jennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, Emily A. Saunderson, Billy M. C. Jebaraj, Daniela Steinbrecher, Anna Dolnik, Tamara J. Blätte, Dan A. Landau, Jenny Saub, Sven Estenfelder, Stefan Ibach, Florence Cymbalista, Veronique Leblond, Alain Delmer, Jasmin Bahlo, Sandra Robrecht, Kirsten Fischer, Valentin Goede, Lars Bullinger, Catherine J. Wu, Daniel Mertens, Gabriella Ficz, John G. Gribben, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer

    Published 2020-05-01
    Get full text
    Article
  14. 14
    Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)

    Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG) by Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, Jeremy Franklin, Can Zhang, Christian Maurer, Nisha De Silva, Elisabeth Lange, Rudolf Weide, Michael G. Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling-Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Marco Herling, Kirsten Fischer, Hartmut Döhner, Michael Kneba, Clemens-Martin Wendtner, Wolfram Klapper, Karl-Anton Kreuzer, Sebastian Böttcher, Stephan Stilgenbauer, Anna Maria Fink, Michael Hallek, Barbara Eichhorst

    Published 2020-02-01
    Get full text
    Article
  15. 15
    Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia

    Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia by Johannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, Billy Michael Chelliah Jebaraj, Sandra Robrecht, Julia Krzykalla, Heng Pan, Adam Giza, Gulnara Akylzhanova, Karlheinz Holzmann, Annika Scheffold, Harvey E. Johnston, Ru-Fang Yeh, Tetyana Klymenko, Eugen Tausch, Barbara Eichhorst, Lars Bullinger, Kirsten Fischer, Martin Weisser, Tadeusz Robak, Christof Schneider, John Gribben, Lekh N. Dahal, Mathew J. Carter, Olivier Elemento, Dan A. Landau, Donna S. Neuberg, Mark S. Cragg, Axel Benner, Michael Hallek, Catherine J. Wu, Hartmut Döhner, Stephan Stilgenbauer, Daniel Mertens

    Published 2021-09-01
    Get full text
    Article

Search Tools: